冠状动脉与外周动脉疾病患者抗血小板联合口服抗凝治疗
本文是一篇深度综述,讨论血小板与凝血因子在动脉粥样硬化血栓形成中的作用,并回顾在冠状动脉和外周动脉疾病患者中联合使用抗血小板与口服抗凝治疗的原理与临床证据。文章指出,尽管采用最强效P2Y12抑制剂,急性冠脉综合征后第一年仍有约十分之一患者发生复发性血栓事件,这促使探索在抗血小板基础上加用抗凝药或极低剂量口服抗凝替代阿司匹林的策略。
要点
- 急性冠脉综合征后首年约十分之一患者仍发生复发性血栓事件,即使使用最强效P2Y12抑制剂。
- 双联抗血小板治疗(阿司匹林+氯吡格雷)较阿司匹林单药降低血栓事件,奠定治疗范式。
- 综述探讨极低剂量口服抗凝联合抗血小板或替代阿司匹林的策略及凝血因子抑制的非经典效应。
核心结论
- 抗血小板治疗是冠状动脉和外周动脉急慢性疾病治疗的基石,但长期最佳抗血栓策略仍存问题。
- 在急性冠脉综合征稳定后患者中,探索极低剂量口服抗凝联合抗血小板或替代阿司匹林的策略具有理论基础与临床研究价值。
研究设计与样本
- 本文为深度综述,回顾血小板与凝血因子在动脉粥样硬化血栓形成中的作用及联合抗栓治疗的原理与临床证据。
主要发现
- 阿司匹林联合氯吡格雷双联抗血小板治疗较阿司匹林单药降低急性冠脉综合征及经皮冠状动脉介入治疗患者的血栓事件率。
- 比氯吡格雷药效动力学更强的P2Y12抑制剂与更少血栓事件相关,进一步巩固了双联抗血小板治疗策略。
- 急性冠脉综合征事件后第一年,尽管使用最强效P2Y12抑制剂,仍有约十分之一患者发生复发性血栓事件。
临床怎么用
- 综述提示在急性冠脉综合征稳定后患者中可考虑极低剂量口服抗凝联合抗血小板或替代阿司匹林的策略,但需基于临床证据个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antiplatelet therapy is the mainstay for the treatment of acute and chronic arterial disease involving the coronary and peripheral beds. However, questions remain about optimal antithrombotic therapy for long-term treatment of chronic vascular disease. The observation that dual antiplatelet therapy with acetylsalicylic acid and clopidogrel was associated with lower thrombotic event rates than acetylsalicylic acid monotherapy in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention changed the treatment paradigm. Moreover, the demonstration that more pharmacodynamically potent P2Y12 inhibitors than clopidogrel were associated with fewer thrombotic event occurrences further solidified the dual antiplatelet therapy approach. However, recurrent thrombotic events occur in ≈1 in 10 patients in the first year following an acute coronary syndrome event, despite treatment with the most potent P2Y12 inhibitors, a limitation that has stimulated interest in exploring the efficacy and safety of approaches using anticoagulants on top of antiplatelet therapy. These investigations have included treatment with very-low-dose oral anticoagulation, and even its replacement of acetylsalicylic acid in the presence of a P2Y12 inhibitor, in patients stabilized after an acute coronary syndrome event. Recent basic and translational studies have suggested noncanonical effects of coagulation factor inhibition that may further modulate clinical benefits. This in-depth review will discuss developments in our understanding of the roles that platelets and coagulation factors play in atherothrombosis and review the rationale and clinical evidence for combining antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease.
引用
- Gurbel PA, Fox KAA, Tantry US, et al. Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation. 2019. PMID: 31034291. doi:10.1161/CIRCULATIONAHA.118.033580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。